“Ozempic damages your kidneys.”
What the evidence shows
For its main population, the direction of effect is the opposite of the myth. In the FLOW trial (3,533 people with type 2 diabetes and chronic kidney disease), once-weekly semaglutide cut major kidney events — big drops in kidney function, kidney failure, or kidney/cardiovascular death — by about 24%, and the trial was stopped early for benefit. A kidney analysis of the SELECT trial suggested the protection extends to non-diabetic people with obesity and heart disease. The genuine kidney risk is indirect and short-term: severe vomiting or diarrhea (usually during dose escalation) can cause dehydration, which can trigger acute kidney injury. This is why the FDA label warns about acute kidney injury from volume depletion, a bigger concern in older patients or those on diuretics, ACE inhibitors/ARBs, or NSAIDs.
What we still don’t know
The dehydration-driven kidney injury risk in ordinary real-world use (versus closely monitored trials) isn't precisely quantified, and how much slow titration and hydration prevent it is more clinical common sense than trial-proven. The kidney benefit is strongest in people who actually have kidney disease or diabetes; whether a healthy person gets meaningful renal protection is not the point the trials tested.
Why the claim misleads
"Damages your kidneys" inverts the best evidence, which shows a protective effect in the populations studied. It collapses a real but manageable, reversible dehydration risk — get sick, get dry, stress the kidneys — into a false claim of direct organ toxicity. The practical takeaway is to stay hydrated and loop in a clinician during bad GI spells, especially on blood-pressure or anti-inflammatory drugs — not to fear the medicine is corroding your kidneys.
Graded by The Peptide Era · evidence, not hype